拓新药业 (301089.SZ)

今开: 最高: 成交量:

昨收: 最低: 成交额:

+ 收藏

利润表(单季度)(拓新药业)

导出到EXCEL
报表日期选择
  • 常用日期查询
  • 自定义年度查询
    日期范围
    报告期
    报告类型
    显示选项
关 闭
完整财报对比
2024年第三季度2024年第二季度2024年第一季度2023年第四季度2023年第三季度2023年第二季度2023年第一季度
上市前/上市后 上市后上市后上市后上市后上市后上市后上市后
报表类型 合并报表合并报表合并报表合并报表合并报表合并报表合并报表
一、营业总收入(元) 106,997,011.86110,434,198.42108,322,506.6889,382,087.4889,151,674.77105,969,013.34551,007,175.69
 营业收入(元) 106,997,011.86110,434,198.42108,322,506.6889,382,087.4889,151,674.77105,969,013.34551,007,175.69
二、营业总成本(元) 118,691,711.86119,163,467.51111,604,696.36150,714,507.97110,356,588.37110,798,605.55145,292,581.58
 营业成本(元) 77,026,258.9785,064,822.4079,986,578.97126,215,638.1464,289,093.9566,320,073.4095,127,708.27
 研发费用(元) 12,744,814.587,922,217.708,246,051.3416,306,824.9513,010,020.5816,468,977.075,463,699.61
 营业税金及附加(元) 2,206,164.971,706,258.611,277,369.641,744,738.681,538,640.152,152,922.217,583,373.87
 销售费用(元) 3,497,585.003,926,087.822,100,833.34842,919.313,119,389.873,260,261.012,606,320.90
 管理费用(元) 22,863,379.5622,202,102.1820,722,760.066,249,538.1529,014,589.7624,492,082.6634,717,917.60
 财务费用(元) 353,508.78-1,658,021.20-728,896.99-645,151.26-615,145.94-1,895,710.80-206,438.67
  其中:利息费用(元) --620.5252,011.0346,381.25-46,381.25285,058.95
  其中:利息收入(元) 446,748.971,330,262.91487,280.892,323,539.34-789,656.62789,656.62965,427.81
 资产减值损失(元) ----6,618,127.55-511,488.22--
 信用减值损失(元) 737,250.9332,938.562,385,995.352,528,482.891,031,210.31531,217.70-8,576,001.12
三、其他经营收益
 加:公允价值变动收益(元) 81,117.81160,219.18-704,998.30704,998.30-1,127,289.671,127,289.67-158,127.86
 加:投资收益(元) 1,009,519.97500,074.031,453,695.62280,612.162,775,938.112,132,546.811,380,136.61
 资产处置收益(元) ---4,909.59----
 其他收益(元) 3,866,690.294,405,582.432,629,281.784,224,246.593,312,779.401,105,419.972,830,960.49
四、营业利润(元) -6,000,121.00-3,625,545.302,476,875.18-60,212,208.10-15,723,763.67-3,571,658.35401,191,562.23
 加:营业外收入(元) 65,027.5753,205.6429,957.52-0.011,000.00362.9660.00
 减:营业外支出(元) 3,628,814.65213,122.3954,627.142,869,531.56246,434.16349,205.771,686,813.78
五、利润总额(元) -9,563,908.08-3,785,462.052,452,205.56-63,081,739.67-15,969,197.83-3,920,501.16399,504,808.45
 减:所得税费用(元) -8,689,452.0462,242.87383,823.737,036,359.47-19,627,087.23-9,147,215.7195,198,578.88
六、净利润(元) -874,456.04-3,847,704.922,068,381.83-70,118,099.143,657,889.405,226,714.55304,306,229.57
(一)按经营持续性分类
  持续经营净利润(元) -874,456.04-3,847,704.922,068,381.83-70,118,099.143,657,889.405,226,714.55304,306,229.57
(二)按所有权归属分类
  归属于母公司股东的净利润(元) -874,456.04-3,847,704.922,068,381.83-70,118,099.143,657,889.405,226,714.55304,306,229.57
 扣除非经常性损益后的净利润(元) -2,374,938.89-7,325,571.65-641,436.44-72,307,966.57116,850.091,629,710.90302,531,567.98
七、每股收益
 一、基本每股收益(元) -0.01-0.030.02-0.560.030.042.42
 二、稀释每股收益(元) -0.01-0.030.02-0.560.030.042.42
九、综合收益总额(元) -874,456.04-3,847,704.922,068,381.83-72,244,456.083,657,889.405,226,714.55304,306,229.57
 归属于母公司所有者的综合收益总额(元) -874,456.04-3,847,704.922,068,381.83-72,244,456.083,657,889.405,226,714.55304,306,229.57
公告日期 2024-10-262024-08-242024-04-232024-04-232023-10-252023-08-252023-04-26
审计意见(境内) 标准无保留意见

前瞻产业研究院